For information, the company have announced that trial did not meet one of its dual primary endpoints (OS) and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
 
Status Suspended
Technology type Medicine
Decision Selected
Process TA
ID number 3948

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 May 2023 For information, the company have announced that trial did not meet one of its dual primary endpoints (OS) and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
10 May 2023 Suspended. For information, the company have announced that trial did not meet one of its dual primary endpoints (OS) and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual